Ipsen SA
PAR:IPN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
100.7
125.8
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one IPN stock under the Base Case scenario is 148.83 EUR. Compared to the current market price of 111.3 EUR, Ipsen SA is Undervalued by 25%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Ipsen SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for IPN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Ipsen SA is a dynamic biopharmaceutical group based in France that has carved a significant niche in the global healthcare landscape. Founded in 1929, the company has evolved into a key player in the development of innovative medicines specializing in oncology, neuroscience, and rare diseases. With a strong commitment to research and development, Ipsen aims to address unmet medical needs by delivering transformative treatments. Its robust pipeline includes promising products that have garnered attention for their potential impact on patient outcomes, particularly in cancer therapies and treatments for debilitating conditions such as severe muscle spasms. Investors find Ipsen compelling due t...
Ipsen SA is a dynamic biopharmaceutical group based in France that has carved a significant niche in the global healthcare landscape. Founded in 1929, the company has evolved into a key player in the development of innovative medicines specializing in oncology, neuroscience, and rare diseases. With a strong commitment to research and development, Ipsen aims to address unmet medical needs by delivering transformative treatments. Its robust pipeline includes promising products that have garnered attention for their potential impact on patient outcomes, particularly in cancer therapies and treatments for debilitating conditions such as severe muscle spasms. Investors find Ipsen compelling due to its strategic focus on high-growth therapeutic areas, bolstered by a strong sales force and expanding global footprint.
As a publicly traded company, Ipsen has demonstrated a solid financial performance while adhering to a disciplined approach towards investments and operational efficiency. The firm’s commitment to sustainability and ethical practices enhances its reputation and aligns with the increasing demand for corporate responsibility in the healthcare sector. With a record of strategic acquisitions and partnerships, Ipsen is well-positioned to enhance its portfolio and leverage synergies for future growth. As the healthcare landscape continues to evolve, investors are drawn to Ipsen’s potential for long-term value creation, leveraging its innovative pipeline and strategic execution to support its mission of improving patients’ lives worldwide.
Ipsen SA is a global biopharmaceutical group focused on innovation and specialty care. The company's core business segments can be categorized as follows:
-
Oncology: This is one of Ipsen’s primary areas of focus, where it develops and markets treatments for various types of cancer. The portfolio includes products for neuroendocrine tumors, prostate cancer, and other indications. Ipsen has established itself with therapies that target specific cancer pathways, contributing to improved clinical outcomes.
-
Neuroscience: In this segment, Ipsen focuses on treatments for neurological conditions. This includes therapies for movement disorders such as cervical dystonia and spasticity. The company has a robust pipeline aimed at addressing unmet medical needs in the neuroscience area.
-
Rare Diseases: Ipsen is committed to developing treatments for rare diseases, particularly those that impact patients with unique medical needs. This includes products that target specific conditions often overlooked by larger pharmaceutical companies.
-
Consumer Health: While a smaller segment of its portfolio, Ipsen develops over-the-counter medications and dietary supplements. This area further diversifies its offerings and revenue streams.
Ipsen operates globally, with a strong presence in Europe, North America, and growing markets in Asia. The company emphasizes innovation, investing in research and development to expand its product pipeline and improve existing therapies, aligning with its strategic vision to provide health solutions that significantly impact patient lives.
Ipsen SA is a global biopharmaceutical group that specializes in the development and commercialization of innovative medicines in areas such as oncology, neurology, and endocrinology. Here are some unique competitive advantages that Ipsen SA may hold over its rivals:
-
Focused Therapeutic Areas: Ipsen has a concentrated portfolio in specific therapeutic areas, particularly oncology, which allows for deep expertise and innovation in these fields. This focus can enhance their ability to develop effective treatments and build strong relationships with healthcare professionals.
-
Strong R&D Pipeline: Ipsen invests significantly in research and development, leading to a robust pipeline of innovative therapies. Their commitment to innovation, particularly in niche areas, can provide differentiation from competitors.
-
Orphan Drug Designation: Many of Ipsen's products may target rare diseases, which can offer regulatory advantages, such as faster approvals and market exclusivity. This can lead to less competition in specific market segments.
-
Global Reach with Local Expertise: Ipsen operates in many countries, leveraging both global scale and local market knowledge. Their ability to navigate various regulatory environments and cultural contexts can facilitate successful product launches and adaptations.
-
Strategic Partnerships and Collaborations: Ipsen has established partnerships with other pharmaceutical companies and research institutions. Such collaborations can enhance their R&D capabilities and market reach without incurring all the associated costs.
-
Patient-Centric Approach: Ipsen is focused on patient needs, which can lead to higher satisfaction and loyalty among healthcare providers and patients. Their emphasis on personalized medicine may also align well with current trends in healthcare.
-
Experienced Management Team: Leadership with significant industry experience can provide strategic insight and foster innovation within the company. An experienced team can better navigate market dynamics and steer the company towards growth.
-
Established Brand and Reputation: With years of operation in the biopharmaceutical industry, Ipsen has built a strong brand and reputation. This can facilitate easier access to healthcare professionals and institutions, compared to newer or lesser-known competitors.
-
Financial Stability: As a well-established player in the industry, Ipsen may have greater financial resources to invest in R&D and marketing than smaller rivals, allowing for sustained competitive advantages.
-
Sustainable Practices: Increasing focus on sustainability and corporate social responsibility can enhance a company's reputation and appeal to certain market segments. Ipsen's commitment to ethical practices can distinguish it from competitors.
These competitive advantages enable Ipsen SA to position itself strongly in the pharmaceutical industry, navigate challenges effectively, and capitalize on opportunities for growth.
Ipsen SA, a global biopharmaceutical group focused on innovating and developing drugs, particularly in oncology and rare diseases, faces several risks and challenges in the near future:
-
Regulatory Risks: Navigating complex regulatory environments across different regions can be challenging. A delay or rejection of new drug applications by regulatory bodies like the FDA or EMA can significantly impact revenue.
-
Market Competition: The biopharmaceutical industry is highly competitive, with numerous players developing similar products. The entry of generic drugs or new treatment options from competitors can erode Ipsen's market share.
-
Pipeline Development: Ipsen’s future growth depends on its ability to innovate and bring new products to market. If clinical trials for new drugs fail or experience delays, it could jeopardize future revenue streams.
-
Patent Expiry: As patents for key products expire, Ipsen could face increased competition from generics, which would adversely affect sales and profitability.
-
Supply Chain Disruptions: Global supply chain challenges, exacerbated by geopolitical tensions or health crises (like pandemics), can affect the manufacturing and distribution of products.
-
Pricing Pressure: Increasing scrutiny on drug pricing and calls for transparency in the pharmaceutical industry may lead to lower prices or reduced reimbursement rates from insurers, impacting margins.
-
Adverse Events and Liability Risks: Any reports of serious side effects associated with Ipsen's products could lead to liability claims, damage to reputation, and reduced sales.
-
Economic Conditions: Global economic uncertainty, including inflation or recession, can influence healthcare budgets and spending on pharmaceuticals, affecting sales.
-
Technological Advances: Rapid advancements in biotechnology may lead to faster development of competing products or alternatives, which could challenge Ipsen's offerings.
-
Talent Acquisition and Retention: Attracting and retaining skilled professionals in a competitive labor market is crucial for innovation and operational efficiency.
Keeping an eye on these risks and effectively strategizing to mitigate them is essential for maintaining Ipsen's market position and facilitating growth in the coming years.
Revenue & Expenses Breakdown
Ipsen SA
Balance Sheet Decomposition
Ipsen SA
Current Assets | 1.9B |
Cash & Short-Term Investments | 493.5m |
Receivables | 761.2m |
Other Current Assets | 645.1m |
Non-Current Assets | 4.6B |
Long-Term Investments | 141.4m |
PP&E | 594.2m |
Intangibles | 3.6B |
Other Non-Current Assets | 348.6m |
Current Liabilities | 1.7B |
Accounts Payable | 857.6m |
Short-Term Debt | 17.9m |
Other Current Liabilities | 789.7m |
Non-Current Liabilities | 835.1m |
Long-Term Debt | 351.3m |
Other Non-Current Liabilities | 483.8m |
Earnings Waterfall
Ipsen SA
Revenue
|
3.4B
EUR
|
Cost of Revenue
|
-618m
EUR
|
Gross Profit
|
2.8B
EUR
|
Operating Expenses
|
-2.2B
EUR
|
Operating Income
|
586.5m
EUR
|
Other Expenses
|
94.7m
EUR
|
Net Income
|
681.2m
EUR
|
Free Cash Flow Analysis
Ipsen SA
EUR | |
Free Cash Flow | EUR |
IPN Profitability Score
Profitability Due Diligence
Ipsen SA's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Ipsen SA's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
IPN Solvency Score
Solvency Due Diligence
Ipsen SA's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Score
Ipsen SA's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IPN Price Targets Summary
Ipsen SA
According to Wall Street analysts, the average 1-year price target for IPN is 129.4 EUR with a low forecast of 111.1 EUR and a high forecast of 171.15 EUR.
Dividends
Current shareholder yield for IPN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
IPN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. The company is headquartered in Boulogne-Billancourt, Ile-De-France. The company went IPO on 2005-12-06. The firm operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one IPN stock under the Base Case scenario is 148.83 EUR.
Compared to the current market price of 111.3 EUR, Ipsen SA is Undervalued by 25%.